ReviewGene therapy2005
Intracellular trafficking of retroviral vectors: obstacles and advances.
Review in Gene therapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Improved alpharetrovirus-based Gag.MS2 particles for efficient and transient delivery of CRISPR-Cas9 into target cells.Molecular therapy. Nucleic acids · 2022Article
- Quantitative monitoring of the cytoplasmic release of NCp7 proteins from individual HIV-1 viral cores during the early steps of infection.Scientific reports · 2019Article
- Biomaterial-guided delivery of gene vectors for targeted articular cartilage repair.Nature reviews. Rheumatology · 2019Review
- The Impact of the CD9 Tetraspanin on Lentivirus Infectivity and Exosome Secretion.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- SJP-L-5, a novel small-molecule compound, inhibits HIV-1 infection by blocking viral DNA nuclear entry.BMC microbiology · 2015Article
- Intracellular trafficking of hybrid gene delivery vectors.Journal of controlled release : official journal of the Controlled Release Society · 2015Article
- Efficient in vitro gene delivery by hybrid biopolymer/virus nanobiovectors.Journal of controlled release : official journal of the Controlled Release Society · 2014Article
- Strategies on the nuclear-targeted delivery of genes.Journal of drug targeting · 2013Review
- Characteristics of the cellular receptor influence the intracellular fate and efficiency of virus infection.Journal of virology · 2013Article
- Article
- Visualization of DC-SIGN-mediated entry pathway of engineered lentiviral vectors in target cells.PloS one · 2013Article
- Enhanced real-time monitoring of adeno-associated virus trafficking by virus-quantum dot conjugates.ACS nano · 2011Article
- Attenuated Salmonella typhimurium carrying shRNA-expressing vectors elicit RNA interference in murine bladder tumors.Acta pharmacologica Sinica · 2011Article
- Interplay between HIV entry and transportin-SR2 dependency.Retrovirology · 2011Article
- Optimal cytoplasmic transport in viral infections.PloS one · 2009Article
- Learning from the viral journey: how to enter cells and how to overcome intracellular barriers to reach the nucleus.The AAPS journal · 2009Review
- Visualization of targeted transduction by engineered lentiviral vectors.Gene therapy · 2008Article
- Intranuclear trafficking of episomal DNA is transcription-dependent.Molecular therapy : the journal of the American Society of Gene Therapy · 2007Article
- Retroviral proteins that interact with the host cell cytoskeleton.Current opinion in immunology · 2007Review
- The road to chromatin - nuclear entry of retroviruses.Nature reviews. Microbiology · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Retroviruses are efficient vehicles for delivering transgenes in vivo. Their ability to integrate into the host genome, providing a permanent imprint of their genes in the host, is a key asset for gene therapy. Furthermore, the lentivirus subset of retroviruses can infect nondividing as well as dividing cells. This expands the cell types capable of gene therapy, driving the development of lentiviral vectors. However, the precise mechanisms used by different retroviruses to efficiently deliver their genes into cell nuclei remains largely unclear. Understanding these molecular mechanisms may reveal features to improve the efficacy of current retroviral vectors. Moreover, this knowledge may expose elements pliable to other gene therapy vehicles to improve their in vivo performance and circumvent the biosafety concerns of using retroviral vectors. Therefore, the mechanisms underlying the early trafficking of retroviral vectors in host cells are reviewed here, as understood from studying the native retroviruses. Events after virus entry up to nuclear delivery of the viral cDNA are discussed. Cellular obstacles faced by these retroviral vectors and how they advance beyond these barriers is emphasized.
Indexed as
Identifiers
16292352What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.